脐血造血干/祖细胞部分归巢受体功能缺陷的研究  

Functional Defect of Partial Homing Receptor on Human Cord Blood Hematopoietic Stem/Progenitor Cells

作　　者：张旭晗[1] 孙自敏[1] 刘会兰[1] 王兴兵[1] 耿良权[1] 

机构地区：[1]安徽医科大学附属安徽省立医院血液科,安徽合肥230001

出　　处：《中国实验血液学杂志》2010年第2期445-449,共5页Journal of Experimental Hematology

基　　金：安徽省国际合作项目编号:08080703026

摘　　要：本研究旨在了解来源于脐血造血干细胞表面部分归巢受体(homing receptor)的功能缺陷并探讨体外干预的效果和可行性。用流式细胞术对来源于脐血的CD34+造血干/祖细胞表面的P、E选择蛋白配体活性基团表达、CD26的表达及活性进行检测,同时检测骨髓和外周血作为对照。采用岩藻糖基转移酶体外处理脐血CD34+造血干/祖细胞并检测其表面选择蛋白配体活性基团的表达水平。结果表明,CD26在脐血、骨髓及外周血的CD34+造血干/祖细胞表面的表达率分别为:(7.62±0.63)%,(6.35±0.89)%和(6.18±0.91)%(p>0.05),其活性分别为:67.15U/1 000个细胞(1U=1pmol/min),26.85U/1 000个细胞和20.95U/1 000个细胞,脐血CD34+造血干/祖细胞表面CD26的活性明显高于其它两者(p<0.001)。P选择蛋白配体活性基团在脐血、骨髓和外周血CD34+造血干/祖细胞表面的表达率分别为:(83.46±6.33)%,(15.65±0.89)%和(80.17±6.85)%;E选择蛋白配体活性基团的表达率为:(25.31±1.03)%,(26.34±0.89)%和(29.79±1.78)%(p>0.05)。脐血CD34+细胞体外行岩藻糖基化工程后,E选择蛋白配体活性基团表达率由(25.31±1.03)%提高至(63.23±1.08)%。结论:3种不同来源CD34+造血干/祖细胞表面的CD26分子表达无明显差别,但其活性不一,脐血的CD34+造血干/祖细胞CD26活性最高,骨髓的次之,外周血的最低。P选择蛋白配体活性基团在脐血及外周血CD34+造血干/祖细胞表面的表达无明显差别,但在骨髓干细胞表面表达偏低。体外经岩藻糖基化工程处理的脐血CD34+造血干/祖细胞可明显上调其表面E选择蛋白配体活性基团的表达。This study was aimed to investigate the function defect of partial homing receptor on cord blood hematopoietic stem cells （CBHSC） and explore efficacy and feasibility of intervention in vitro. The expression and activity of active groups in P, E-selectin ligands on CD34^＋ cells from cord blood, bone marrow and peripheral blood were detected by flow cytometry; meanwhile the expression of active groups in selectin ligands on CD34^＋ cells treated by fucosyl transferase in vitro was determined by flow cytometry. The results indicated that the expression levels of CD26 on the surface of stern/progenitor cells （CD34^＋ ） from cord blood, bone marrow and peripheral blood were （7.62 ± 0.63 ） %, （6.35 ± 0.89） % and （ 6. 18 ± 0.91 ） % （p 〉 0.05 ） respectively. And the activites of CD26 of the three sources of stem cells were 67.15 U/1 000 cells（ 1 U = 1 pmoi/min） ,26.85 U/1 000 cells and 20.95 U/1 000 cells respectively, in which the activity of CD26 on surface of CD34^＋ from cord blood was significantly higher than that from other both sources （p 〈0.01 ）. The expression levels of P-selectin ligand on the stern/progenitor ceils three kinds were （ 83.46 ± 6.33 ） %, （ 15.65 ± 0.89 ） % and （ 80.17_± 6.85 ） %, and the expression levels of E-selectin ligand on stem/ progenitor cells of three kinds were （ 25.31 ± 1.03 ） %, （26.34 ± 0.89 ） % and （ 29.79 ± 1.78 ） % respectively . The expression of E-selectin ligand on the surface of cord blood stem/progenitor cell CD34^＋ increased from （25.31± 1. 03 ） % to （63.23 ± 1.08 ） % after glycosylation engineering. It is concluded that there is no significant difference of the expreesion of CD26 between the three sources of stem/progenitor cells, but the activity of CD26 in cord blood was obviously higher than that in bone marrow and peripheral blood. The expression of P-selectin ligand on bone marrow stern/progenitor cell was lower than that on stem cells of cord blood and peripheral blood. Glycosylati

关 键 词：造血干细胞 归巢 CD26 选择素配体 糖基 

分 类 号：R457.7[医药卫生—治疗学]